Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPHENE 65 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Relief of mild to moderate pain,FDA-approved for pain management (withdrawn due to cardiac toxicity)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active metabolite with longer half-life). Minor metabolism via N-demethylation and glucuronidation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Propoxyphene: ~78% bound to albumin; norpropoxyphene: ~95% bound to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution: 16-20 L/kg (suggesting extensive tissue binding). Clinical meaning: high Vd indicates wide distribution into tissues, contributing to long half-life and potential for accumulation.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: approximately 30-70% (first-pass metabolism). Other routes: not formulated for parenteral use.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl < 30 m L/min: Avoid use due to accumulation of toxic metabolite norpropoxyphene. Cr Cl 30-50 m L/min: Reduce dose to 50 mg every 6 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class C: Contraindicated. Child-Pugh Class B: Avoid use or reduce dose by 50% with close monitoring.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended for use in pediatric patients due to risk of respiratory depression and lack of established safety.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at lowest dose (e.g., 50 mg every 6 hours) and titrate cautiously; avoid in patients with renal impairment or concomitant CNS depressants.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: RISK OF CARDIAC TOXICITY AND OVERDOSE. Propoxyphene has been withdrawn from the US market due to risk of fatal cardiac arrhythmias (QT prolongation, torsade de pointes) even at therapeutic doses. Use with alcohol or other CNS depressants increases risk of respiratory depression and death.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Cardiac toxicity (QT prolongation, torsade de pointes); respiratory depression; CNS depression (additive with alcohol/other depressants); risk of abuse and dependence; renal or hepatic impairment; elderly patients; history of head injury; increased intracranial pressure; seizure disorders; acute abdominal conditions.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to propoxyphene or opioid cross-sensitivity; known QT prolongation; concurrent use of MAO inhibitors; severe asthma or respiratory depression; obstructive airway disease; paralytic ileus; pregnancy and breastfeeding.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions; avoid excessive grapefruit juice as it may increase propoxyphene levels.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trimester: Limited data; potential for oligohydramnios. Third trimester: Premature closure of ductus arteriosus, fetal renal dysfunction with oligohydramnios, and neonatal pulmonary hypertension. Avoid in third trimester unless compelling need.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted into breast milk in small amounts; M/P ratio approximately 0.7. Clinical studies show no adverse effects in infants at therapeutic maternal doses. However, due to potential for prostaglandin inhibition, caution is advised, especially in premature infants or those with platelet dysfunction. Consider monitoring infant for bruising, bleeding, or gastrointestinal effects.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No standard dose adjustment recommended for pregnancy. However, due to increased volume of distribution and renal clearance in pregnancy, lower plasma concentrations may occur. Clinical efficacy should guide therapy; dosing at the lower end of the recommended range (e.g., 325 mg every 4-6 hours) is prudent to minimize fetal exposure. Avoid high doses and chronic use in third trimester.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Propoxyphene is a weak opioid analgesic; avoid in patients with suicidal ideation or history of substance abuse due to risk of overdose and cardiac toxicity (QT prolongation). Use with caution in elderly and renal impairment; start at lower doses. Monitor for respiratory depression, especially when combined with CNS depressants.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not increase dose or frequency.,Do not consume alcohol or other CNS depressants.,May cause dizziness or drowsiness; avoid driving until known effect.,Report any signs of allergic reaction or irregular heartbeat.,Do not stop abruptly; withdrawal symptoms may occur.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPHENE 65 vs ABSTRAL, answered by our medical review team.
PROPHENE 65 is a Opioid Analgesic that works by Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPHENE 65 and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPHENE 65 is: Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPHENE 65 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPHENE 65 is classified as Category C. FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trime. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.